These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14522477)

  • 1. Confusion in reperfusion.
    Gibson CM
    J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
    Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
    J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
    Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
    Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
    Nordt TK; Peter K; Bode C
    Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
    Vahanian A
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated percutaneous coronary intervention in patients with acute myocardial infarction transferred from remote hospitals.
    Dudek D; Zmudka K; Kaluza GL; Kuta M; Pieniazek P; Przewlocki T; Zorkun C; Legutko J; Gajos G; Bartuś S; Bryniarski L; Dziewierz A; Pasowicz M; Dubiel JS
    Am J Cardiol; 2003 Jan; 91(2):227-9. PubMed ID: 12521638
    [No Abstract]   [Full Text] [Related]  

  • 11. [The FINESSE trial].
    Petronio AS; Piscione F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):1-5. PubMed ID: 19292014
    [No Abstract]   [Full Text] [Related]  

  • 12. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
    Califf RM
    Am Heart J; 1999 Jul; 138(1 Pt 2):S12-5. PubMed ID: 10385786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy for acute myocardial infarction: combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneous coronary intervention.
    Herrmann HC
    Am J Cardiol; 2000 Apr; 85(8A):10C-6C. PubMed ID: 10793175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimal thrombolysis].
    Nordt TK; Bode C
    Z Kardiol; 2001 Aug; 90(8):591-5. PubMed ID: 11565215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.